Ki-67 in endometrial cancer: Scoring optimization and prognostic relevance for window studies

Sarah Kitson, Vanitha N Sivalingam, James Bolton, Rhona McVey, Mashid Nickkho-Amiry, Melanie E. Powell, Alexandra Leary, Hans W. Nijman, Remi A. Nout, Tjalling Bosse, Andrew G. Renehan, Henry C. Kitchener, Richard J. Edmondson, Emma J. Crosbie*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

69 Citations (Scopus)
315 Downloads (Pure)

Abstract

Ki-67, a marker of cellular proliferation, is increasingly being used in pre-surgical window studies in endometrial cancer as a primary outcome measure. Unlike in breast cancer, however, there are no guidelines standardizing its measurement and its clinical relevance as a response biomarker is undetermined. It is, therefore, imperative that Ki-67 scoring protocols are optimized and its association with patient survival rigorously evaluated, in order to be able to clinically interpret the results of these studies. Using the International Ki-67 in Breast Cancer Working Group guidelines as a basis, whole slide, hot spot and invasive edge scoring protocols were evaluated using endometrial biopsies and hysterectomy specimens from 179 women. Whole sections and tissue microarrays, manual and semi-automated scoring using Definiens Developer software were additionally compared. Ki-67 scores were related to clinicopathological variables and cancer-specific survival in uni-and multivariate analysis. Against criteria of time efficiency, intra-and inter-observer variability and consistency, semi-automated hot spot scoring was the preferred method. Ki-67 scores positively correlated with grade, stage and depth of myometrial invasion (P-values all <0.03). By univariate analysis, higher Ki-67 scores were associated with a significant reduction in cancer-specific survival (P

Original languageEnglish
Pages (from-to)459-468
Number of pages10
JournalModern Pathology
Volume30
Issue number3
DOIs
Publication statusPublished - Mar-2017

Keywords

  • BREAST-CANCER
  • ENDOCRINE THERAPY
  • PROLIFERATION
  • CARCINOMA
  • METFORMIN
  • EXPRESSION
  • KI67
  • MARKER
  • TRIAL

Fingerprint

Dive into the research topics of 'Ki-67 in endometrial cancer: Scoring optimization and prognostic relevance for window studies'. Together they form a unique fingerprint.

Cite this